NLRP3 and Parkinson disease: It has also been reported that newly diagnosed PD patients have increased systemic IL-1β levels in the serum (Williams‐Gray et al., 2016), and systemic NLRP3 inflammasome expression and activation are correlated with motor severity and progression in PD (Fan et al., 2020).